載入...
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an enormous challenge to the medical system, especially the lack of safe and effective COVID-19 treatment methods, forcing people to look for drugs that may have therapeutic effects as...
Na minha lista:
| 發表在: | Eur J Pharmacol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
The Authors. Published by Elsevier B.V.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7746509/ https://ncbi.nlm.nih.gov/pubmed/33345848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2020.173813 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|